Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sasanlimab With or Without BCG in Non-Muscle Invasive Bladder Cancer
NCT04165317Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of sasanlimab in non-muscle-invasive bladder cancer (NMIBC) (5 arms), sponsored by Pfizer. Primary endpoint: Event Free Survival up to 257.1 weeks. Started Dec 2019; status: active, not recruiting.
02
Drugs
sasanlimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04165317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165317.